METTL3 and osteosarcoma: Miao et al. demonstrated that METTL3 silencing decreased the expression of lymphoid enhancer-binding factor 1 (LEF1) because knockdown of METTL3 reduced the m6A level and shortened the half-life of LEF1 mRNA transcripts and subsequently inhibited the wnt/β-catenin pathway in human osteosarcoma (46).